Aktuellt
SENASTE
Redeye continue to see an exciting case in Nanologica despite the Q4 report falling short of sales and EBIT estimates, with write-downs impacting the results. We maintain a positive outlook as follow-up orders are poised to generate considerable sales in the quarters ahead, the company targets SEK100m in 2024 sales.
LÄS MER
